Education
About Us
Working with TipRanks
Follow Us
Dishman Carbogen Amcis Ltd. (IN:DCAL)
:DCAL
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹167.65 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹27.00B
Enterprise Value₹46.37B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)22.7
Beta1.43
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio-10.28
Price to Book (P/B)0.58
Price to Sales (P/S)1.25
P/FCF Ratio21.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Steady Revenue GrowthSustained 81.49% gross margin combined with multi-year revenue growth (~6.6%) indicates durable unit economics and pricing power in its CDMO/API businesses. High gross margins provide structural room to absorb SG&A and R&D while funding scale-up of manufacturing for long-term contracts.
Improving Operating Profitability (EBIT/EBITDA Recovery)A recovery in EBIT/EBITDA margins signals management progress on cost control and project execution efficiency. For a CDMO, improved operating margins reflect better project ramp methodology and throughput, which are durable improvements that enhance free cash generation over contract lifecycles.
Strong Cash Generation And Manageable LeverageNear-doubling of free cash flow and operating cash flow comfortably above net income indicate improving cash conversion and liquidity. Combined with a solid equity ratio and moderate leverage, this provides financial flexibility to invest in capacity, meet long-duration CDMO commitments, and fund selective capex without stress.
Bears Say
Very Thin Net ProfitabilityA net margin near zero constrains retained earnings and reduces the firm’s ability to build reserves or return capital to shareholders. Persistently minimal net profits may indicate structural cost or non-operating pressures that erode the benefit of high gross margins, limiting long-term shareholder value creation.
Very Low Return On EquityROE near zero implies the company is not effectively translating equity into earnings. Over months, this signals weak capital efficiency and raises questions about management’s ability to deploy capital into high-return projects, potentially constraining growth funding and investor confidence over the medium term.
Suboptimal Free Cash Flow Conversion Vs Net IncomeOnly about half of reported net income converting to free cash flow limits internal funding for capex, working capital needs, or dividends. For a capital-intensive CDMO, inconsistent FCF conversion raises the risk that growth investments may require external financing, reducing long-term margin stability.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹167.65 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹27.00B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is May 12, 2026 which is in 69 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on Feb 03, 2026. The company reported -₹0.827 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.827.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of -₹0.827 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.012%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―